Determinants of response to cancer immunotherapy

癌症免疫治疗反应的决定因素

• 批准号: 10458030
• 负责人: Lawrence Fong
• 金额: $ 94.96万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-01 至 2028-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10458030
• 关键词: Advanced Malignant Neoplasm; Antigens; Antitumor Response; Basic Science; Blood; CD4 Positive T Lymphocytes; Cancer Patient; Cells; Clinical; Clinical Trials; Clone Cells; Combination immunotherapy; Drug Targeting; Future; Genomics; Goals; Immune; Immune checkpoint inhibitor; Immunosuppression; Immunotherapy; Knock-out; Maps; Mediating; Modality; Neoadjuvant Therapy; Operative Surgical Procedures; Pathway interactions; Patients; Positioning Attribute; Proteomics; Research; Resected; Resistance; T cell receptor repertoire sequencing; T-Lymphocyte; Therapeutic; Translating; Translational Research; anti-tumor immune response; base; bench to bedside; cancer immunotherapy; cancer therapy; cell type; combinatorial; cytotoxic; design; experience; functional plasticity; high dimensionality; immune checkpoint blockade; insight; interest; mouse model; multidisciplinary; neoplastic cell; novel; response; single-cell RNA sequencing; success; tumor

PROJECT SUMMARY/ABSTRACT While immunotherapy is transforming cancer treatment, the majority of patients do not achieve durable responses. We have been studying response and resistance to different immune checkpoint inhibitors and are now poised to propose mechanistic studies aimed at providing an understanding of the immune states and pathways that mediate or inhibit response to immune checkpoint blockade. Using high-dimensional unbiased single-cell RNA-seq (scRNAseq), we can identify both canonical and non-canonical immune effectors that can mediate anti-tumor responses. We believe that non-canonical effectors such as cytotoxic CD4 T cells, which we have recently described, are not effectively triggered by our current treatments. Using the same single-cell approaches, we can identify both known and novel cell types in cancer patients that can mediate immune suppression. In our first objective, we will determine whether combination immunotherapies that include drug(s) targeting specific immunosuppressive cells can enhance the function of these cytotoxic CD4+ T cells. By leveraging neoadjuvant clinical trials where patients receive immunotherapy prior to surgery, we will use single cell genomics and proteomics to define whether these combinations can 1) target the desired immunosuppressive mechanisms, and 2) enhance canonical and/or non-canonical effectors within the resected tumors. We will also use this approach to determine whether we can map these specific cell states into the circulating compartment. The second objective is based on a longstanding interest in our group to define the dynamics of antigen-specific responses. Using single-cell T cell receptor sequencing, we can identify expanded T cell clones as well as follow their localization. In addition to understanding how immunotherapy combinations induce and modulate specific T cell clonotypes within the tumor, we can determine how immunotherapies can induce functional plasticity to desired or undesired states. The third objective builds on our 20 year experience using mouse models to dissect mechanisms underlying response or resistance to immunotherapy. We will determine the functional significance of non-canonical immune effectors using depletion and knock-out strategies. We will also determine how combination immunotherapies can elicit both effective or ineffective anti- tumor immune responses, thereby guiding the design of future clinical trials. In conclusion, our proposal is based on hypothesis-driven bench-to-bedside and bedside-to-bench mechanistic studies with the goal of advancing cancer immunotherapy. With our deep expertise in this field, experience leading multi-disciplinary teams focused on translational research, and a rich network of basic science and clinical collaborators; we are uniquely positioned to succeed in the research plan outlined in this proposal.

项目总结/摘要 虽然免疫疗法正在改变癌症治疗，但大多数患者并没有实现持久的免疫治疗。 应答我们一直在研究对不同免疫检查点抑制剂的反应和耐药性， 现在准备提出机制研究，旨在提供对免疫状态的理解， 介导或抑制对免疫检查点阻断的反应的途径。使用高维无偏 通过单细胞RNA-seq（scRNAseq），我们可以鉴定典型和非典型免疫效应物， 介导抗肿瘤反应。我们认为，非典型效应细胞，如细胞毒性CD 4 T细胞，我们认为， 我们目前的治疗方法并不能有效地触发这些症状。使用相同的单细胞 通过这种方法，我们可以在癌症患者中识别出已知的和新的细胞类型，这些细胞可以介导免疫反应。 镇压在我们的第一个目标中，我们将确定包括药物在内的联合免疫疗法是否 靶向特异性免疫抑制细胞可以增强这些细胞毒性CD 4 + T细胞的功能。通过 利用患者在手术前接受免疫治疗的新辅助临床试验，我们将使用单次免疫治疗。 细胞基因组学和蛋白质组学，以确定这些组合是否可以1）靶向所需的 免疫抑制机制，和2）增强切除的肿瘤内的典型和/或非典型效应物。 肿瘤的我们还将使用这种方法来确定我们是否可以将这些特定的细胞状态映射到 循环舱第二个目标是基于我们集团的长期利益， 抗原特异性反应的动力学。使用单细胞T细胞受体测序，我们可以识别扩增的 T细胞克隆以及跟踪它们的定位。除了了解免疫疗法组合如何 诱导和调节肿瘤内的特异性T细胞克隆型，我们可以确定免疫疗法如何 将功能可塑性诱导到期望或不期望的状态。第三个目标是基于我们20年的经验 使用小鼠模型来剖析免疫疗法的反应或抵抗的潜在机制。我们将 使用消耗和敲除确定非典型免疫效应物的功能意义 战略布局我们还将确定联合免疫疗法如何引起有效或无效的抗- 肿瘤免疫反应，从而指导未来临床试验的设计。总之，我们的建议是基于 关于假设驱动的实验室到床边和床边到实验室机制研究，目的是推进 癌症免疫疗法凭借我们在该领域的深厚专业知识，经验领导多学科团队专注于 在转化研究，以及基础科学和临床合作者的丰富网络;我们是独一无二的 能够成功完成本提案中概述的研究计划。